Table 2

Important cointerventions to be prospectively collected

CointerventionVariable to captureOperationalisation
Vasospasm*7 10 13 48 49
 Vasospasm prophylaxisHyperdynamic therapy (prior to diagnosis of vasospasm)

  • Use of vasopressors to drive a target MAP>65 mm Hg

  • Use of intravenous fluid infusions or regular boluses over maintenance

  • Use of intravenous fluids to target specific haematocrit

Magnesium (prior to diagnosis of vasospasm)

  • Use of magnesium intravenous infusion

Chemical vasodilators (prior to diagnosis of vasospasm)

  • Use of infusion of vasodilator (intravenous) or any IA use (eg, milrinone, paperavine, CCB, etc)

 Vasospasm treatmentHyperdynamic therapy (after diagnosis of vasospasm)

  • Same criteria as above

Magnesium

  • Same criteria as above

Mechanical vasodilation

  • Use of balloon angioplasty

Chemical vasodilation

  • Use of infusion of vasodilator (intravenous) or any IA use (eg, milrinone, paperavine, CCB, etc).

Definitive aneurysm management (if completed postrandomisation)6 24Clip vs coil

  • Used or not

Time to clip or coil

  • Minutes

Blood pressure management31Daily use of vasopressor

  • Used or not

Highest daily target MAP

  • mm Hg

Fever/temperature regulation5 48fever

  • Daily highest temperature

  • *Radiographic vasospasm defined as a reduction in cerebral artery diameter on digital subtraction angiography and classified as mild (0–33% reduction), moderate (34–66% reduction) or severe (67–100% reduction) or by transcranial Doppler with a mean middle or anterior cerebral artery flow velocity of >200 cm/s or an increase of >50 cm/s/24 hours on repeated measures and a Lindegaard ratio of ≥3, clinical vasospasm requires the radiographic diagnosis with clinical neurological deterioration (defined as an otherwise unexplained decrease in Glasgow Coma Scale score of ≥2 points for ≥2 hours or new focal neurological deficit).

  • CCB, calcium channel blocker; IA, intra-arterial; IV, intravenous; MAP, mean arterial pressure.